{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:54:48Z","timestamp":1794318888626,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-87232-z","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T18:16:54Z","timestamp":1737397014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Plasma S100A8\/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Tadahiro","family":"Kuribayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichiro","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Makimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kammei","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Kiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Toyooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakiyo","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadoaki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"3","key":"87232_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"87232_CR2","first-page":"1","volume":"41","author":"MD Shields","year":"2021","unstructured":"Shields, M. D., Marin-Acevedo, J. A. & Pellini, B. Immunotherapy for Advanced non-small cell lung cancer: A decade of progress. Am. Soc. Clin. Oncol. Educ. Book. 41, 1\u201323 (2021).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"4","key":"87232_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14(4), 847\u2013856 (2015).","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"87232_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","volume":"12","author":"C Valero","year":"2021","unstructured":"Valero, C. et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat. Commun. 12(1), 729 (2021).","journal-title":"Nat. Commun."},{"issue":"5","key":"87232_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian, S. L. et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16(5), 275\u2013287 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"87232_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2019.02.009","volume":"130","author":"T Jiang","year":"2019","unstructured":"Jiang, T. et al. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1\/PD-L1 inhibitors. Lung Cancer 130, 76\u201383 (2019).","journal-title":"Lung Cancer"},{"issue":"46","key":"87232_CR7","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1038\/onc.2016.104","volume":"35","author":"C Hernandez","year":"2016","unstructured":"Hernandez, C., Huebener, P. & Schwabe, R. F. Damage-associated molecular patterns in cancer: A double-edged sword. Oncogene 35(46), 5931\u20135941 (2016).","journal-title":"Oncogene"},{"key":"87232_CR8","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3389\/fimmu.2018.01298","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. S100A8\/A9 in inflammation. Front. Immunol.\u00a09, 1298 (2018).","journal-title":"Front. Immunol."},{"issue":"4","key":"87232_CR9","doi-asserted-by":"publisher","first-page":"100753","DOI":"10.1016\/j.tranon.2020.100753","volume":"13","author":"N Tomonobu","year":"2020","unstructured":"Tomonobu, N., Kinoshita, R. & Sakaguchi, M. S100 soil sensor receptors and molecular targeting therapy against them in cancer metastasis. Transl Oncol. 13(4), 100753 (2020).","journal-title":"Transl Oncol."},{"issue":"1","key":"87232_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s40425-019-0828-1","volume":"7","author":"NB Wagner","year":"2019","unstructured":"Wagner, N. B. et al. Tumor microenvironment-derived S100A8\/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J. Immunother Cancer 7(1), 343 (2019).","journal-title":"J. Immunother Cancer"},{"issue":"3","key":"87232_CR11","first-page":"100484","volume":"4","author":"S Miura","year":"2023","unstructured":"Miura, S. et al. Effectiveness and safety of atezolizumab monotherapy in previously treated Japanese patients with unresectable advanced or recurrent NSCLC: A multicenter, prospective, observational study (J-TAIL). JTO Clin. Res. Rep. 4(3), 100484 (2023).","journal-title":"JTO Clin. Res. Rep."},{"issue":"22","key":"87232_CR12","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1002\/cam4.6645","volume":"12","author":"JH Goldschmidt","year":"2023","unstructured":"Goldschmidt, J. H. et al. Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy. Cancer Med. 12(22), 20783\u201320797 (2023).","journal-title":"Cancer Med."},{"issue":"1","key":"87232_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jtho.2017.10.030","volume":"13","author":"J Tanizaki","year":"2018","unstructured":"Tanizaki, J. et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J. Thorac. Oncol. 13(1), 97\u2013105 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"87232_CR14","doi-asserted-by":"publisher","first-page":"827788","DOI":"10.3389\/fimmu.2022.827788","volume":"13","author":"CL Han","year":"2022","unstructured":"Han, C. L. et al. The predictive potential of the baseline C-reactive protein levels for the efficiency of Immune checkpoint inhibitors in cancer patients: A systematic review and meta-analysis. Front. Immunol. 13, 827788 (2022).","journal-title":"Front. Immunol."},{"key":"87232_CR15","doi-asserted-by":"publisher","first-page":"1039121","DOI":"10.3389\/fmolb.2022.1039121","volume":"9","author":"DC Guven","year":"2022","unstructured":"Guven, D. C. et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci. 9, 1039121 (2022).","journal-title":"Front. Mol. Biosci."},{"issue":"10","key":"87232_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00011-018-1173-4","volume":"67","author":"F Shabani","year":"2018","unstructured":"Shabani, F. et al. Calprotectin (S100A8\/S100A9): A key protein between inflammation and cancer. Inflamm. Res. 67(10), 801\u2013812 (2018).","journal-title":"Inflamm. Res."},{"key":"87232_CR17","doi-asserted-by":"publisher","first-page":"1187741","DOI":"10.3389\/fphar.2023.1187741","volume":"14","author":"H Zhou","year":"2023","unstructured":"Zhou, H. et al. The functions and regulatory pathways of S100A8\/A9 and its receptors in cancers. Front. Pharmacol. 14, 1187741 (2023).","journal-title":"Front. Pharmacol."},{"key":"87232_CR18","doi-asserted-by":"crossref","unstructured":"Sprenkeler, E. G. G. et al. S100A8\/A9 is a marker for the release of neutrophil extracellular traps and induces neutrophil activation. Cells 11(2), 236 (2022).","DOI":"10.3390\/cells11020236"},{"issue":"19","key":"87232_CR19","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20(19), 5064\u20135074 (2014).","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"87232_CR20","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl. J. Med. 366(26), 2443\u20132454 (2012).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"87232_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12943-020-01260-z","volume":"19","author":"L Horvath","year":"2020","unstructured":"Horvath, L. et al. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC): Novel approaches and future outlook. Mol. Cancer 19(1), 141 (2020).","journal-title":"Mol. Cancer"},{"key":"87232_CR22","doi-asserted-by":"publisher","first-page":"104633","DOI":"10.1016\/j.ebiom.2023.104633","volume":"92","author":"F Ghiringhelli","year":"2023","unstructured":"Ghiringhelli, F. et al. Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1\/PD-L1 immunotherapy in non-small cell lung cancer. EBioMedicine 92, 104633 (2023).","journal-title":"EBioMedicine"},{"issue":"12","key":"87232_CR23","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.jtho.2021.07.027","volume":"16","author":"M Shirasawa","year":"2021","unstructured":"Shirasawa, M. et al. Differential immune-related microenvironment determines programmed cell death protein-1\/programmed death-ligand 1 blockade efficacy in patients with advanced NSCLC. J. Thorac. Oncol. 16(12), 2078\u20132090 (2021).","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"87232_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"87232_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/ijc.31982","volume":"145","author":"R Kinoshita","year":"2019","unstructured":"Kinoshita, R. et al. Newly developed anti-S100A8\/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis. Int. J. Cancer 145(2), 569\u2013575 (2019).","journal-title":"Int. J. Cancer"},{"key":"87232_CR26","first-page":"94","volume":"6","author":"J Futami","year":"2016","unstructured":"Futami, J. et al. An efficient method for the preparation of preferentially heterodimerized recombinant S100A8\/A9 coexpressed in Escherichia coli. Biochem. Biophys. Rep. 6, 94\u2013100 (2016).","journal-title":"Biochem. Biophys. Rep."},{"issue":"4","key":"87232_CR27","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","volume":"4","author":"G Ritchie","year":"2018","unstructured":"Ritchie, G. et al. Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: A systematic review and meta-analysis. JAMA Oncol. 4(4), 522\u2013528 (2018).","journal-title":"JAMA Oncol."},{"issue":"6230","key":"87232_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124\u2013128 (2015).","journal-title":"Science"},{"key":"87232_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","volume":"106","author":"SJ Bagley","year":"2017","unstructured":"Bagley, S. J. et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106, 1\u20137 (2017).","journal-title":"Lung Cancer"},{"issue":"3","key":"87232_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita, L. et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 4(3), 351\u2013357 (2018).","journal-title":"JAMA Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87232-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87232-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87232-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T18:16:57Z","timestamp":1737397017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87232-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["87232"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-87232-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kadoaki Ohashi has received honoraria from Eli Lilly Japan K.K., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Kyowa Kirin Co., Ltd., and Novartis Pharma K.K; grants from Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Amgen K.K., and Novartis Pharma K.K; and receipt of research reagents from Genentech, Inc. and Novartis Pharma K.K. outside the submitted work. Kiichiro Ninomiya has received honoraria from AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., Kyowa Kirin Co., Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., MSD K.K., Ono Pharmaceutical CO., LTD., Takeda Pharmaceutical CO., LTD., Pfizer Japan Inc., Bristol Myers Squibb K.K., Elekta K.K., Janssen Pharmaceutical K.K., Amgen K.K., and Daiichi Sankyo Co., Ltd. outside the submitted work. Eiki Ichihara received honoraria from AstraZeneca K.K., Novartis Pharma K.K., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Bristol Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical CO., LTD., and Boehringer Ingelheim; and research fund from Janssen Pharmaceutical K.K., Pfizer Japan Inc., Bristol Myers Squibb K.K., Ono Pharmaceutical Co. Ltd., and Takeda Pharmaceutical CO., LTD. outside the submitted work. Katsuyuki Kiura has received honoraria from AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., Merk Biopharma, TAIHO PHARMACEUTICAL CO., LTD., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical CO., LTD., Eli Lilly Japan K.K., Pfizer Japan Inc. Bristol Myers Squibb K.K., NipponKayaku Co., Ltd., Ono Pharmaceutical Co., Ltd., and MSD K.K.; research fund from Nippon Boehringer-Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Takeda Pharmaceutical CO., LTD., Teijin pharma Ltd., Kyorin Pharmaceutical Co., Ltd., Shionogi Pharma Co., Ltd., Nippon Kayaku Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., and Chugai Pharmaceutical Co., Ltd.; and consulting fees from Nippon Kayaku Co., Ltd., and Nipro Corp. outside the submitted work. Katsuyuki Hotta has received honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Bristol Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., Nippon Boehringer-Ingelheim Co., Ltd., NipponKayaku Co., Ltd., Amgen K.K., TAIHO PHARMACEUTICAL CO., LTD., Merck Biopharma Co., Ltd.; and research fund from MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Bristol Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., and Abbvie Inc. outside the submitted work. Tadahiro Kuribayashi, Rie Kinoshita, Go Makimoto, Toshio Kubo, Kammei Rai, Masahiro Tabata, Yoshinobu Maeda, Shinichi Toyooka, and Masakiyo Sakaguchi declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2577"}}